Review ArticlesMagnetic Resonance Imaging of Prostate Adenocarcinoma Detection and StagingWard, Ryan D. MD*; Purysko, Andrei S. MD†Author Information *Department of Abdominal Imaging, Massachusetts General Hospital, Boston, MA †Department of Abdominal Imaging and Nuclear Radiology, Imaging Institute, Cleveland Clinic, Cleveland, OH. Address correspondence to Andrei S. Purysko, MD, Department of Abdominal Imaging and Nuclear Radiology, Imaging Institute, Cleveland Clinic, 9500 Euclid Ave, Mail code JB3, Cleveland, OH 44195 (e-mail: firstname.lastname@example.org). Received 8 November, 2019 Accepted 2 December, 2019 The authors report no conflicts of interest. Topics in Magnetic Resonance Imaging: February 2020 - Volume 29 - Issue 1 - p 17-30 doi: 10.1097/RMR.0000000000000226 Buy Metrics Abstract Prostate cancer (PCa) is common among men worldwide and is a major cause of morbidity and mortality. The detection of PCa has historically followed a stepwise process of prostate-specific antigen screening followed with systematic transrectal ultrasound-guided biopsy. Magnetic resonance imaging (MRI), utilizing a set of sequences to assess morphology and function, has gained clinical acceptance to detect, characterize, and stage PCa. The Prostate Imaging – Reporting and Data System has helped facilitate the standardization of reporting across institutions and increased adoption of this method. In this review, we will (1) discuss the strengths and weaknesses of conventional diagnostic methods; (2) describe the clinical utility of prostate MRI, specifically addressing its uses in the detection and staging of PCa; and (3) list important technical parameters required for state-of-the-art prostate MRI. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.